Morgan Stanley raised the firm’s price target on Cigna (CI) to $361 from $355 and keeps an Overweight rating on the shares after the firm hosted meetings with management that it says “reinforced the underappreciated” Specialty opportunity. The September investor day will be a platform to emphasize the company’s increasingly Specialty-centric long-term focus, the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna downgraded to Hold from Buy at Deutsche Bank
- Cigna Earns Buy Rating on Strong Free Cash Flow, Deleveraged Balance Sheet, and Double-Digit EPS Growth Outlook
- Cigna Reaffirms 2026 Outlook and Profitability Targets
- Cigna price target raised to $371 from $358 at Bernstein
- Cigna Maintained at Buy on Specialty Pharmacy Strength and Solid Cost Discipline; $338 Price Target Reaffirmed